Physician profile
Richard Larson
NPI 1265074660
$766.50
in general payments reported to CMS, 2019-2025
15 companies · $107 in 2025
The $107 reported for 2025 was more than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $66.02 · 2023: $307 · 2024: $286 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $217.54 | 2022-2024 | Azstarys, Azstarys |
| Ironshore Pharmaceuticals INC. | $156.31 | 2023-2024 | Jornay Pm |
| Modernatx, INC. | $64.02 | 2023 | Moderna Covid-19 Vaccine |
| Sanofi-Aventis U.S. LLC | $55.53 | 2025 | |
| Supernus Pharmaceuticals, INC. | $51.41 | 2023-2024 | Qelbree, Qelbree |
| Seqirus USA INC | $44.71 | 2024 | Flucelvax |
| Collegium Pharmaceutical, INC. | $32.41 | 2025 | Jornay Pm |
| Ironwood Pharmaceuticals, INC | $23.68 | 2024 | |
| Nestle Healthcare Nutrition INC. | $23.20 | 2023 | |
| Tris Pharma INC | $19.31 | 2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $18.95 | 2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Ultragenyx Pharmaceutical INC. | $17.59 | 2023 | |
| Pfizer INC. | $14.76 | 2023 | |
| Sanofi Pasteur INC. | $13.57 | 2024 | |
| Glaxosmithkline, LLC. | $13.51 | 2023 | Pediarix, Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.